Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prince Pharmaceutical CoROCO:6935 -0.50%60 EBITDA Margin % is 19.36% as of Dec. 2025, which is 96% above its 10-year median of 9.86. GuruFocus rates ROCO:6935 with a GF Score™ of 60/100 and a GF Value™ of NT$42.11 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 961 Drug Manufacturers companies, Prince Pharmaceutical Co ranks better than 60.77% on this metric.
Prince Pharmaceutical Co (ROCO:6935) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Prince Pharmaceutical Co EBITDA Margin % Related Terms
Prince Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6935 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Prince Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prince Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prince Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Prince Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prince Pharmaceutical Co (ROCO:6935) has a EBITDA Margin % of 19.36% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prince Pharmaceutical Co and its competitors. This is 96% above median its historical median of 9.86. According to the industry distribution chart, Prince Pharmaceutical Co ranks #377 out of 961 companies in the Drug Manufacturers industry, placing it in the top 39.2%.
Is Prince Pharmaceutical Co's EBITDA Margin % too high?
Prince Pharmaceutical Co's current EBITDA Margin % of 19.36% is 96% above median its 10-year median of 9.86. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Prince Pharmaceutical Co's value of 19.36% is 55% above this industry median. Based on the distribution chart, Prince Pharmaceutical Co ranks #377 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Prince Pharmaceutical Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prince Pharmaceutical Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Prince Pharmaceutical Co ranks #377 out of 961 companies for EBITDA Margin %. This puts Prince Pharmaceutical Co in the upper half of its industry. The industry median EBITDA Margin % is 12.49. Prince Pharmaceutical Co's value of 19.36% is 55% above this benchmark. While the company's 10-year median is 9.86 vs. the industry median of 12.49, Prince Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prince Pharmaceutical Co's current EBITDA Margin % of 19.36% is 55% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prince Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prince Pharmaceutical Co's current EBITDA Margin % is 19.36%, which is 96% above median its own 10-year median of 9.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prince Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Prince Pharmaceutical Co (ROCO:6935) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$42.11, compared to a current price of NT$30.15 — trading 28.4% below its estimated fair value. The current EBITDA Margin % is 19.36%, which is 96% above median its 10-year median of 9.86 and 55% above the Drug Manufacturers industry median of 12.49. Prince Pharmaceutical Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Prince Pharmaceutical Co (ROCO:6935), the current EBITDA Margin % is 19.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prince Pharmaceutical Co (ROCO:6935) Overvalued in 2026?
Based on GuruFocus' analysis, Prince Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$30.15 is trading 28.4% below its estimated GF Value™ of NT$42.11.
GuruFocus considers Prince Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for ROCO:6935:
EBITDA Margin %: 19.36% (96% above median its 10-year median of 9.86)
GF Value™: NT$42.11 vs. price of NT$30.15 (28.4% below fair value)
Industry Position: 55% above the Drug Manufacturers median (#377 of 961)
No single metric tells the full story. See the ROCO:6935 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe and other regions.
60GF Score
Get the complete analysis for ROCO:6935
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6935 has been successfully added to your 
